Mirna Therapeutics Inc. (NASDAQ:MIRN)‘s stock had its “neutral” rating reaffirmed by investment analysts at Leerink Swann in a research report issued on Wednesday.
The analysts wrote, “We maintain our Market Perform rating for Amgen along with our $193 price target.””
MIRN has been the subject of a number of other reports. HC Wainwright initiated coverage on shares of Mirna Therapeutics in a research note on Monday, September 12th. They issued a “buy” rating and a $6.00 price target for the company. Cantor Fitzgerald downgraded shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research raised shares of Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research note on Wednesday, September 7th. Citigroup Inc. downgraded shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $7.00 to $4.50 in a research note on Tuesday, August 16th. Finally, Oppenheimer Holdings Inc. downgraded shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $6.96.
Shares of Mirna Therapeutics (NASDAQ:MIRN) opened at 1.96 on Wednesday. Mirna Therapeutics has a 12-month low of $1.82 and a 12-month high of $11.01. The company’s market cap is $40.84 million. The company has a 50 day moving average of $3.05 and a 200-day moving average of $4.08.
Mirna Therapeutics Company Profile
Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.